Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
about
Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?Tuberculosis: opportunities and challenges for the 90-90-90 targets in HIV-infected childrenBedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis.Getting to 90-90-90 in paediatric HIV: What is needed?Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug.Pharmacokinetic Interactions for Drugs with a Long Half-Life—Evidence for the Need of Model-Based Analysis.Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin.Bedaquiline for the treatment of drug-resistant tuberculosis.Management of drug resistantTB in patients with HIV co-infection.Synthetic investigational new drugs for the treatment of tuberculosis.Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline.New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations.Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB.An automated sampling importance resampling procedure for estimating parameter uncertainty.Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB.A Bayesian response-adaptive trial in tuberculosis: The endTB trial.Outcomes of HIV-infected versus HIV-non-infected patients treated for drug-resistance tuberculosis: Multicenter cohort study.Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill.Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children
P2860
Q26771997-615CB00E-8614-40D2-8B4F-3945B283B14DQ26774267-0F0D022D-9B9B-4B2C-920C-217174CF789CQ26824413-54BBCDD6-F7C2-4A47-8A56-5AEA54B46CB5Q30249515-C1FA189B-B632-42D3-994B-75D33AFE055EQ30385352-0ECED0DD-2086-4191-A04C-2AD656837CE7Q35167188-1962149B-00A5-48C2-8168-CA14872D3349Q36445099-DDA9059B-8C82-42EE-8427-790C4BF1DE85Q37540020-B235A385-A4BC-4FD2-B592-647EC9E39993Q38386950-D4AEB3EF-D80D-4130-99BA-F4312E75DE93Q38610637-FB38DA87-16AF-40C9-A9DA-AC9E842FF508Q38635790-408925F2-827E-4C27-B325-52DB0A4B6D2DQ38995175-90ED2C88-A5DB-42B8-A41B-DA53685CCD61Q39010772-7DA866A2-BEA6-4BA4-B483-6E7BA3C55690Q40076101-DD7F5857-78BF-4D8F-A7DD-7389F0F7FC4FQ40839674-6FFE656F-2486-439D-846C-FCBDAA877ABCQ46078169-A4930895-D2B1-4A10-837D-4B92B8FA7620Q47898423-E9041ED7-583F-4D1E-98A1-D3ADABA20A51Q50170378-B9553A1F-8826-460F-B273-3C2351AA1BB3Q52666801-B2FD10BF-EDA0-4662-9936-6CFF7B7037BAQ55547799-201E53A5-7498-42E7-92F5-53F0CD409352Q58788916-ED964C16-7841-45E2-84F7-036EA762CC2F
P2860
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Impact of lopinavir-ritonavir ...... tuberculosis-HIV coinfection.
@ast
Impact of lopinavir-ritonavir ...... tuberculosis-HIV coinfection.
@en
Impact of lopinavir-ritonavir ...... tuberculosis-HIV coinfection.
@nl
type
label
Impact of lopinavir-ritonavir ...... tuberculosis-HIV coinfection.
@ast
Impact of lopinavir-ritonavir ...... tuberculosis-HIV coinfection.
@en
Impact of lopinavir-ritonavir ...... tuberculosis-HIV coinfection.
@nl
prefLabel
Impact of lopinavir-ritonavir ...... tuberculosis-HIV coinfection.
@ast
Impact of lopinavir-ritonavir ...... tuberculosis-HIV coinfection.
@en
Impact of lopinavir-ritonavir ...... tuberculosis-HIV coinfection.
@nl
P2093
P2860
P356
P1476
Impact of lopinavir-ritonavir ...... tuberculosis-HIV coinfection.
@en
P2093
Elin M Svensson
Kelly E Dooley
Mats O Karlsson
P2860
P304
P356
10.1128/AAC.03246-14
P407
P577
2014-08-11T00:00:00Z